Age‐Related Macular Degeneration
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Age‐related macular degeneration ( AMD ) is the leading cause of blindness in the elderly, and the prevalence of the disease increases exponentially with every decade after age 50 years. It is a multifactorial disease involving a complex interplay of genetic, environmental, metabolic, and functional factors. Besides smoking, hypertension, obesity, and certain dietary habits, a growing body of evidence indicates that inflammation and the immune system may play a key role in the development of the disease. AMD may progress from the early form to the intermediate form and then to the advanced form, where two subtypes exist: the nonneovascular (dry) type and the neovascular (wet) type. The results from the Age‐Related Eye Disease Study have shown that for the nonneovascular type of AMD , supplementation with high‐dose antioxidants (vitamin C, vitamin E, and β‐carotene) and zinc is recommended for those with the intermediate form of AMD in one or both eyes or with advanced AMD or vision loss due to AMD in one eye. As for the neovascular type of the advanced AMD , the current standard of therapy is intravitreal injections of vascular endothelial growth factor inhibitors. In addition, lifestyle and dietary modifications including improved physical activity, reduced daily sodium intake, and reduced intake of solid fats, added sugars, cholesterol, and refined grain foods are recommended. To date, no study has demonstrated that AMD can be cured or effectively prevented. Clearly, more research is needed to fully understand the pathophysiology as well as to develop prevention and treatment strategies for this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“The VEGF family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor, with VEGF-A as the key regulator of both physiologic and pathologic angiogenesis.(43) Thus, VEGF-A has been the target of most anti-VEGF treatments.”
BackgroundA Clinical Trial of the Effects of Dietary Patterns on Blood Pressure
Appel, L. J., Moore, T. J., Obarzanek, E., Vollmer, W. M., Svetkey, L. P., Sacks, F. M., Bray, G. A., Vogt, T. M., Cutler, J. A., Windhauser, M. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704173361601 · Cited by 5,981
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404143301501 · Cited by 4,737
Microglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676 · cited 1×
“They are resident immune cells located in the central nervous system, involved in both innate and adaptive immunity.(38) In the normal adult retina, microglia are quiescent, composed of small and stellate cells strictly limited to the inner retinal layers.”
BackgroundEffects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341802 · Cited by 3,638
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“5 mg or photodynamic therapy (PDT) with verteporfin.(81) PDT with verteporfin was approved by the FDA in 2000 for the treatment of predominantly classic subfoveal CNV.”
MethodRanibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“Pegaptanib was the first anti-VEGF agent approved by the FDA in 2004, following publication of results from two concurrent phase III clinical trials, the VEGF Inhibition Study in Ocular Neovascularization (VISION) trials.(97) The VISION trials demonstrated that intravitreal administration of pegaptanib 0.”
BackgroundBird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
Prevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265 · cited 1×
“It seems likely that drusen deposits represent not only waste that cannot be eliminated but also the byproduct of local active processes involving inflammation, the complement system, and local and systemic immune-related mechanisms.(31) Along this line, the occurrence of AMD drusen in normal aging suggests that this…”
BackgroundThe AMD Genetics Clinical Study Group, Gold, B., Merriam, J. E., Zernant, J., Hancox, L. S., Taiber, A. J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1750 · Cited by 1,075 · cited 1×
“16–18 Genetic studies have suggested that polymorphisms in some genes may account for 74% of cases of AMD, and the complement system involved in factor H and in factor B and C2 genes is one of the major factors in the development of AMD.(19) Other modifiable risk factors for AMD include hypertension, obesity, high die…”
BackgroundThe epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932
Age-related macular degeneration
de Jong, P. T. V. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062326 · Cited by 787
Gupta, N., Brown, K. E., & Milam, A. H. (2003) · Experimental Eye Research · doi:10.1016/s0014-4835(02)00332-9 · Cited by 582
Age-related macular degeneration
Coleman, H. R., Chan, C.-C., Ferris, F. L., & Chew, E. Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61759-6 · Cited by 542
Khan, J. C. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.073643 · Cited by 390
Seddon, J. M. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.12.1728 · Cited by 384
Dietary Antioxidants and the Long-term Incidence of Age-Related Macular Degeneration
Tan, J. S. L., Wang, J. J., Flood, V., Rochtchina, E., Smith, W., & Mitchell, P. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.083 · Cited by 381
Singer, M. A., Awh, C. C., Sadda, S., Freeman, W. R., Antoszyk, A. N., Wong, P., & Tuomi, L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.016 · Cited by 356
Dietary intake of antioxidants and risk of age-related macular degeneration
van Leeuwen, R. (2005) · JAMA · doi:10.1001/jama.294.24.3101 · Cited by 345
A Prospective Study of Cigarette Smoking and Risk of Age-Related Macular Degeneration in Men
Christen, W. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140035023 · Cited by 320
VandenLangenberg, G. M., Mares-Perlman, J. A., Klein, R., Klein, B. E. K., Brady, W. E., & Palta, M. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009625 · Cited by 234
Age related macular degeneration and drusen: Neuroinflammation in the retina
Buschini, E., Piras, A., Nuzzi, R., & Vercelli, A. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.05.011 · Cited by 230 · cited 1×
“27 Recently, a growing body of evidence showed that inflammation and the immune system play a key role in triggering this disease in both subtypes of advanced AMD.(28) Although AMD is not considered a classic inflammatory disease, inflammatory cells, such as macrophages and giant cells, have been reported to localize…”
BackgroundStewart, M. W., Rosenfeld, P. J., Penha, F. M., Wang, F., Yehoshua, Z., Bueno-Lopez, E., & Lopez, P. F. (2011) · Retina · doi:10.1097/iae.0b013e31822c290f · Cited by 225
SanGiovanni, J. P., Agrón, E., Meleth, A. D., Reed, G. F., Sperduto, R. D., Clemons, T. E., & Chew, E. Y. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27594 · Cited by 186
Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab
Eghøj, M. S., & Sørensen, T. L. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2011.203893 · Cited by 143
Age-related macular degeneration and the immune response: implications for therapy
Nussenblatt, R. B., & Ferris, F. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.06.025 · Cited by 130 · cited 1×
“The loss of RPE cells seems crucial in allowing excessive activation of the immunologic inflammatory cascade, which results in disease pathogenesis and progression and the development of complications.(37) In addition to macrophages, microglial cells are involved in the pathogenesis of AMD.”
BackgroundOtani, A., Takagi, H., Oh, H., Koyama, S., Ogura, Y., Matumura, M., & Honda, Y. (2002) · Microvascular Research · doi:10.1006/mvre.2002.2407 · Cited by 128 · cited 2×
“VEGF—a diffuse cytokine that promotes angiogenesis and vascular permeability—has been implicated as an important factor promoting neovascularization (wet type AMD), as well as other retinopathies.(42) The VEGF family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor, with VEGF-A as the key regula…”
Background
Cited by
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Lipid nanoparticles for the posterior eye segment
Bonilla, L., Espina, M., Severino, P., Cano, A., Ettcheto, M., Camins, A., García, M. L., Souto, E. B., & Sánchez-López, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010090 · Cited by 76
Zhou, C., Hu, X., Tang, C., Liu, W., Wang, S., Zhou, Y., Zhao, Q., Bo, Q., Shi, L., Sun, X., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa033 · Cited by 69
Nanoparticulate drug delivery to the retina
Li, Q., Weng, J., Wong, S. N., Thomas Lee, W. Y., & Chow, S. F. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00224 · Cited by 59
Ruiz-Moreno, J. M., Arias, L., Abraldes, M. J., Montero, J., Udaondo, P., & The RAMDEBURS study group (2021) · International Ophthalmology · doi:10.1007/s10792-021-01906-x · Cited by 41
Metadata
- Authors
- Cheung, L. K., & Eaton, A.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2013-04-11
- Volume
- 33
- Issue
- 8
- Pages
- 838-855
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W4211015941
- Cited by
- 120
- References
- 34
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.